Local ablative radiotherapy: A means ... - Advanced Prostate...

Advanced Prostate Cancer

22,350 members28,110 posts

Local ablative radiotherapy: A means to revert low volume castration-resistant prostate cancer into a hormone-sensitive status?

tango65 profile image
8 Replies

Sounds promising. These patients had a PSADT of 3.2 months before RT. After RT, it took 15.6 months for the PSA to increase from nadir to nadir+2. Looking forward to the prospective study.

----------

ascopubs.org/doi/abs/10.120...

---------

Conclusions: A relevant subset of patients with 68Ga PSMA-PET-detected oligometastatic low volume CRPC had a meaningful PSA-response with aRT. They were reverted into an earlier stage of their disease again. A prospective clinical trial on this clinically highly relevant question is being prepared.

Written by
tango65 profile image
tango65
To view profiles and participate in discussions please or .
Read more about...
8 Replies
NPfisherman profile image
NPfisherman

Nice find....thanks for posting...

Fish

Tall_Allen profile image
Tall_Allen

Unfounded conclusion. Here's why (let's put aside the fact that it was only noted in 15 patients):

1) In metastatic disease, the larger mets put out most of the PSA. That's because metastases create their own (leaky) blood supply, and that is the only way their PSA can leach out into the serum.

2) There is no question that radiation ablates cancer cells. By destroying the largest source of PSA, PSA will go down (after an initial increase).

3) Metastases are always some mixture of hormone sensitive and resistant clones. Older mets, the larger ones that become visible on scans, have a higher percentage of hormone-resistant clones.

4) By ablating the metastases with more hormone-resistant clones, one is left with only micrometastases that do not put out as much PSA. There is no "reversion." The cancer responds to ADT just as it always did, but it wasn't apparent, because hormone-resistance was judged by rising PSA.

In short, all the authors accomplished is "treating PSA" rather than treating the underlying cancer (which would require systemic therapy). They would have to look at the effect on survival to reach a conclusion that it was beneficial.

Addendum:

The lead author wrote to me that he largely agrees with me. He speculates that PSMA-based imaging can preferentially detect the androgen independent clones. He says that only large randomized clinical trials can ascertain whether there is a benefit to metastasis-directed therapy. He apologized for the provocative headline (journal editors often supply the headline).

PhilipSZacarias profile image
PhilipSZacarias in reply toTall_Allen

I agree, reversion is the wrong descriptive term to use to describe the response to ablative SBRT. After reading the paper, I concluded that the intergenetic variability of metastases would result in some being more resistant than others to hormone therapy, and that it was a more probabilistic process that some men were able to continue to be hormone sensitive. The visible metastases that got zapped happened to be more resistant. I like the size issue that you mention. Cheers, Phil

Fairwind profile image
Fairwind

TA is correct. We will all be dead of old age before this goes anywhere..Depending of course on how much money you are willing to spend someplace outside the U.S.

j-o-h-n profile image
j-o-h-n in reply toFairwind

Old Age? From your lips to God's ears...

I hope you have a Mexcellent Cinco de Mayo!

Good Luck, Good Health and Good Humor.

j-o-h-n Sunday 05/05/2019 12:29 PM DST

GP24 profile image
GP24

Balsam01 did post a link to a more detailed follow-up article of this group:

healthunlocked.com/advanced...

Here are slides from a presentation by Dr. Lohaus (SABR beginning at slide 13):

degro.org/ag-stereotaxie/wp...

GP24 profile image
GP24

I think debulking the tumor is beneficial. Both in the hormone-sensitive and castration resistent situation. Patients with a low volume disease have a better prognosis than patients with a high-volume disease. Debulking reduces the tumor volume.

Gravis G, et al., Eur Urol (2018), 10.1016/j.eururo.2018.02.001

Patient summary: Patients with a higher burden of metastatic prostate cancer starting androgen deprivation therapy (ADT) have a poorer prognosis and are more likely to benefit from early docetaxel. Low-volume patients have longer overall survival with ADT alone, and the toxicity of docetaxel may outweigh its benefits.

Parker et al., The Lancet, Oct 21, 2018, 10.1016/S0140-6736(18)32486-3

From table 2: survival at 3 years in the control group: Low metastatic burden 62%, High metastatic burden 37%

monte1111 profile image
monte1111

I used to think I was smart. The people around me thought I was smart. I am extremely humbled by the people on this site. You all remind me of the James dude on Jeopardy. I watch him and think WTF. Thanks to all of you for all that you give us. My doctor has prescribed the chemo and the drugs, but I come here to find out the why. I hope you all enjoy this day.

Not what you're looking for?

You may also like...

Just hit the news stand

Interesting reading regarding nadir and other things.... Be sure to click on the charts....

Docetaxel & PSA time to nadir.

New study below [1]. Here is another of those studies that associate a longer time to lowest PSA...
pjoshea13 profile image

Nadir PSA & time to nadir during initial ADT - & prognosis

New study below. Adding to the evidence that a slower response to ADT is better. "We reviewed the...
pjoshea13 profile image

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in CRPC

New Chinese study below [1]. It's tempting to think of a short time to PSA nadir (lowest point) as...
pjoshea13 profile image

Rapidly decreasing level of PSA during ADT is a risk factor for early progression to CRPC.

New study - odd finding? "... a velocity of PSA decline >11 ng/mL per month (HR 2.124 ...), and a...
pjoshea13 profile image